ArticleFrontiers in immunology2026
Clinical analysis of 19 patients with tuberculosis complicated by hemophagocytic lymphohistiocytosis.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: To systematically describe the clinical characteristics of tuberculosis (TB) complicated by hemophagocytic lymphohistiocytosis (HLH), with the aim of informing early diagnosis, precise classification, and therapeutic decision-making. Methods: A total of 19 hospitalized patients diagnosed with TB-HLH between January 2020 and December 2025 were consecutively enrolled. Based on the presence of disseminated TB, patients were divided into a disseminated group (n = 10) and a non-disseminated group (n = 9). Demographic data, clinical symptoms, laboratory parameters, imaging findings, treatment regimens, and clinical outcomes were systematically collected and compared between the two groups. Results: No statistically significant differences were observed in baseline characteristics such as age and gender between the two groups (P > 0.05). Common clinical symptoms included fever, fatigue, weight loss, and hepatosplenomegaly. Central nervous system symptoms (e.g., headache, impaired consciousness) were observed only in the disseminated group (4 cases vs. 0 case, P = 0.033). The disseminated group had significantly lower serum C-reactive protein (CRP) levels compared to the non-disseminated group (73.20 ± 42.38 mg/L vs. 125.41 ± 61.45 mg/L, P = 0.044). Eighteen patients received anti-tuberculosis therapy, one patient with AIDS discontinued treatment due to critical illness. Glucocorticoids were administered to 16 patients as adjunct therapy for HLH. Among the three patients who did not receive steroids, one had a short disease course and mild bone marrow suppression, one presented with concurrent acute hepatic and renal failure, and one exhibited hematologic and symptomatic improvement following after anti-TB treatment. The overall mortality rate was 21.1% (4/19). Conclusion: This study suggests that central nervous system symptoms serve as a critical indicator for disseminated TB complicated by HLH. The inflammatory profile in TB-HLH exhibits unique features, such as relatively lower CRP in disseminated cases. Clinical management requires a combination of effective anti-TB therapy and a stratified immunomodulatory strategy based on the severity of the hyperinflammatory state.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.